Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to trace Akero Therapeutics’ cash runway or pinpoint when Phase 3 EFX data will hit? Biotech disclosures are dense, and Akero Therapeutics SEC filings explained simply can save hours of scrolling. Our platform tackles the 200-page 10-K so you don’t have to, flagging R&D spend, trial timelines, and risk factors that matter to metabolic-disease investors.
Stock Titan’s AI reads every Akero Therapeutics annual report 10-K simplified, each Akero Therapeutics quarterly earnings report 10-Q filing, and every sudden Akero Therapeutics 8-K material events explained—then turns legal language into plain-English insights. Want real-time alerts? The moment Akero Therapeutics Form 4 insider transactions real-time post to EDGAR, you’ll see executive buys and sells, helping you monitor Akero Therapeutics insider trading Form 4 transactions ahead of critical data releases.
Here’s what you’ll uncover:
- Pipeline clarity: 10-Q sections detailing EFX enrollment progress and FDA feedback.
- Capital health: Cash burn metrics and shelf registrations folded into our Akero Therapeutics earnings report filing analysis.
- Governance insight: The latest Akero Therapeutics proxy statement executive compensation shows incentives tied to NASH milestones.
- Event tracking: AI flags wording changes in new 8-Ks so you understand shifts fast.
- Ownership moves: Instant updates on Akero Therapeutics executive stock transactions Form 4.
Stop piecing together PDFs. With understanding Akero Therapeutics SEC documents with AI, you get clear analysis, real-time feeds, and the context you need to act confidently.
Akero Therapeutics (AKRO) – Form 4 insider transaction
President & CEO Andrew Cheng reported two open-market sales on 10 July 2025 executed under a previously adopted Rule 10b5-1 trading plan dated 16 Aug 2024.
- 14,686 shares sold at a weighted-average price of $50.57.
- 15,314 shares sold at a weighted-average price of $51.732.
- Total shares sold: 30,000; estimated gross proceeds ≈ $1.53 million based on disclosed averages.
- Post-sale direct holdings: 520,757 common shares (down from 550,757), indicating the CEO retains roughly 94% of his prior stake.
No derivative securities were involved. The filing notes that detailed trade-by-trade pricing is available upon request.
While insider sales can signal caution, the modest size (about 5.5 % of Cheng’s holdings) and the existence of a pre-arranged plan reduce potential negative interpretation. There are no indications of material changes to Akero’s operations or outlook within this filing.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
